NHS Logo

Once daily maraviroc 300mg or 150mg OD in combination with ritonavir -boosted darunavir 800/100mg (Record no. 75758)

MARC details
000 -LEADER
fixed length control field 04039cam a2200313 4500
001 - CONTROL NUMBER
control field NMDX6593
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 120401t2012 xxu||||| |||| 00| 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 03057453
100 ## - MAIN ENTRY--PERSONAL NAME
Personal name Okoli, C.
240 ## - UNIFORM TITLE
Uniform title <a href="Journal of Antimicrobial Chemotherapy.">Journal of Antimicrobial Chemotherapy.</a>
245 ## - TITLE STATEMENT
Title Once daily maraviroc 300mg or 150mg OD in combination with ritonavir -boosted darunavir 800/100mg
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT)
Date of publication, distribution, etc. 2012
500 ## - GENERAL NOTE
General note NMUH Staff Publications
500 ## - GENERAL NOTE
General note 67
520 ## - SUMMARY, ETC.
Summary, etc. &lt;br /&gt;&lt;div style="line-height: 17.999801635742188px;"&gt;&lt;h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"&gt;&lt;span style="font-size: 8pt;"&gt;OBJECTIVES:&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em;"&gt;&lt;span style="font-size: 8pt;"&gt;To describe the pharmacokinetics of maraviroc when dosed at 150 or 300 mg once daily with 800/100 mg of darunavir/ritonavir.&lt;/span&gt;&lt;/p&gt;&lt;h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"&gt;&lt;span style="font-size: 8pt;"&gt;METHODS:&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em;"&gt;&lt;span style="font-size: 8pt;"&gt;A retrospective case-note review of HIV-infected adults taking maraviroc was conducted. Patients on a maraviroc-based regimen for a minimum of 5 weeks were grouped as receiving: (i) 300 mg of maraviroc twice daily with 245 mg of tenofovir/200 mg of emtricitabine; (ii) 300 mg of maraviroc once daily with 800/100 mg of darunavir/ritonavir once daily; and (iii) 150 mg of maraviroc once daily with 800/100 mg of darunavir/ritonavir once daily. C(trough) and C(peak) data were collected at 2, 12 or 24 h post-dose.&lt;/span&gt;&lt;/p&gt;&lt;h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"&gt;&lt;span style="font-size: 8pt;"&gt;RESULTS:&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em;"&gt;&lt;span style="font-size: 8pt;"&gt;Sixty-six patients were included, providing 115 samples. The median (IQR) C(peak) was 378 (350-640) ng/mL for 300 mg of maraviroc twice daily with 245 mg of tenofovir/200 mg of emtricitabine (n=9), 728 (378-935) ng/mL for 300 mg of maraviroc once daily with darunavir/ritonavir (n=29) and 364 (104-624) ng/mL for 150 mg of maraviroc once daily with darunavir/ritonavir (n=2; P=0.24). The median (IQR) C(trough) was 46 (33-61) ng/mL for 300 mg of maraviroc twice daily with 245 mg of tenofovir/200 mg of emtricitabine (n=12), 70 (49-97) ng/mL for 300 mg of maraviroc once daily with darunavir/ritonavir (n=34) and 43 (35-55) ng/mL for 150 mg of maraviroc once daily with darunavir/ritonavir (n=17; P=0.001). The maraviroc C(trough) in black patients (n=34) was 61 (45-110) ng/mL and in white patients (n=29) it was 49 (42-70) ng/mL (P=0.04). The C(peak) in black patients (n=20) was 800 (397-1060) ng/mL versus 387 (336-723) ng/mL in white patients (n=20; P=0.02).&lt;/span&gt;&lt;/p&gt;&lt;h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"&gt;&lt;span style="font-size: 8pt;"&gt;CONCLUSIONS:&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em;"&gt;&lt;span style="font-size: 8pt;"&gt;Once daily coadministration of 300 mg of maraviroc with 800/100 mg of darunavir/ritonavir was well tolerated and had favourable pharmacokinetics when compared with 300 mg of maraviroc twice daily with 245 mg of tenofovir/200 mg of emtricitabine. A 24% higher C(trough) and 107% higher C(peak) was seen in black patients compared with white patients.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Siccardi, M.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Thomas-William, S.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Dufty, N.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Khonyongwa, K.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Ainsworth, J.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Watson, J.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Cook, R.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Gandhi, K.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Hickinbottom, G.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Owen, A.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Taylor S.
856 ## - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Once+daily+maraviroc+300mg+or+150mg+OD+in+combination+with+ritonavir+-boosted+darunavir+800%2F100mg">http://www.ncbi.nlm.nih.gov/pubmed/?term=Once+daily+maraviroc+300mg+or+150mg+OD+in+combination+with+ritonavir+-boosted+darunavir+800%2F100mg</a>
856 ## - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="http://jac.oxfordjournals.org/content/67/3/671.full.pdf+html">http://jac.oxfordjournals.org/content/67/3/671.full.pdf+html</a>
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection code Home library Current library Shelving location Date acquired Total Checkouts Date last seen Price effective from Koha item type
        Staff publications for NMDX Ferriman information and Library Service (North Middlesex) Ferriman information and Library Service (North Middlesex) Online 07/06/2022   07/06/2022 07/06/2022 UNKNOWN
London Health Libraries Consortium Privacy notice and Membership terms and conditions